BridgeMD
New treatment option for Ischemic Stroke
Official title Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)
ClinicalTrials.gov ID: NCT06763458
What this study is testing
- What it's testing
- Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke, especially in East and South Asia, and is significantly associated with stroke recurrence and early neurological deterioration (END) despite aggressive medical management. Minor stroke (National Institutes of Health Stroke, NIHSS score ≤ 5) patients with ICAS often has higher risk of END.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Over 18 years of age;
- Minor ischemic stroke within 1 week of onset (NIHSS≤5);
- Have received the best drug treatment (dual antibody, anti-plate combined with anticoagulation), but symptoms still have measurable fluctuations or...
- Symptoms fluctuate to the time of receiving balloon dilation within 24 hours;
- The etiology was considered to be severe stenosis of the responsible vessels due to intracranial arteriosclerosis (70-99% stenosis), or perforator...
You likely can't join if
- Patients who have developed large intracranial vessel occlusion;
- Intracranial hemorrhagic diseases in the past 3 months: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- Non-atherosclerotic disease-related stenosis: arterial dissection, moya-moya disease, arterioinflammatory disease, etc.
- Clotting disorders or systemic bleeding tendency or platelets less than 100,000;
- Complicated with serious infection or liver, kidney and other serious diseases;
- Patients with severe inability to control hypertension (systolic blood pressure \>200mmHg or diastolic blood pressure \>110mmHg);
See the full eligibility criteria
- Over 18 years of age;
- Minor ischemic stroke within 1 week of onset (NIHSS≤5);
- Have received the best drug treatment (dual antibody, anti-plate combined with anticoagulation), but symptoms still have measurable fluctuations or progression (NIHSS increased by at least 1 point);
- Symptoms fluctuate to the time of receiving balloon dilation within 24 hours;
- The etiology was considered to be severe stenosis of the responsible vessels due to intracranial arteriosclerosis (70-99% stenosis), or perforator artery disease with severe stenosis of the carrier artery (confirmed by...
- Patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points;
- Patients or family members sign informed consent.
- Patients who have developed large intracranial vessel occlusion;
- Intracranial hemorrhagic diseases in the past 3 months: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- Non-atherosclerotic disease-related stenosis: arterial dissection, moya-moya disease, arterioinflammatory disease, etc.
- Clotting disorders or systemic bleeding tendency or platelets less than 100,000;
- Complicated with serious infection or liver, kidney and other serious diseases;
- Patients with severe inability to control hypertension (systolic blood pressure \>200mmHg or diastolic blood pressure \>110mmHg);
- Women who are pregnant, have a pregnancy plan or are breastfeeding;
- Complicated with other serious diseases, life expectancy \< 6 months; Other conditions deemed inappropriate for participation in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.